Evidence map›Paper›PMID 38178779›Full record

ReviewPediatrics2024

Advances in the Care of Infants With Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome.

Margarida Mascarenhas, Elisha M Wachman, Iyra Chandra, Rachel Xue, Leela Sarathy, Davida M Schiff

Open access · greenAbstract readReview
In one paragraph

Review in Pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
36.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Neonatal Opioid Withdrawal Syndrome: 2 Years Later…Where Are We NOWS?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
    Article
  7. Association between NNNS-II profiles and pharmacological treatment in infants with prenatal opioid exposure.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Article
  8. Article
  9. Review
  10. Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome.Advances in experimental medicine and biology · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Margarida MascarenhasDivisions of General Academic Pediatrics.
Elisha M WachmanDepartment of Pediatrics, Boston Medical Center, and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Iyra ChandraDana Farber Cancer Institute, Boston, Massachusetts.
Rachel XueDepartment of Family Medicine, Boston Medical Center, Boston, Massachusetts.
Leela SarathyNewborn Medicine, MassGeneral for Children, Boston, Massachusetts.
Davida M SchiffDivisions of General Academic Pediatrics.
Boston Medical Center · USDana-Farber Cancer Institute · USMaineGeneral Medical Center · US

Funding

Safety, pharmacokinetics and efficacy of extended-release naltrexone in pregnant women with opioid use disorderR01HD096798 · NICHD · BOSTON MEDICAL CENTER · PI WACHMAN, ELISHA · 2018 to 2022
$3.4M
Improving Treatment Engagement and Adherence to Optimize Outcomes for Opioid-Exposed Mother-Infant DyadsK23DA048169 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI SCHIFF, DAVIDA · 2019 to 2023
$998k
NICHD NIH HHS R01 HD096798NIDA NIH HHS K23 DA048169
6 · The paper itself

Abstract

A significant number of advances have been made in the last 5 years with respect to the identification, diagnosis, assessment, and management of infants with prenatal opioid exposure and neonatal opioid withdrawal syndrome (NOWS) from birth to early childhood. The primary objective of this review is to summarize major advances that will inform the clinical management of opioid-exposed newborns and provide an overview of NOWS care to promote the implementation of best practices. First, advances with respect to standardizing the clinical diagnosis of NOWS will be reviewed. Second, the most commonly used assessment strategies are discussed, with a focus on presenting new quality improvement and clinical trial data surrounding the use of the new function-based assessment Eat, Sleep, and Console approach. Third, both nonpharmacologic and pharmacologic treatment modalities are reviewed, highlighting clinical trials that have compared the use of higher calorie and low lactose formula, vibrating crib mattresses, morphine compared with methadone, buprenorphine compared with morphine or methadone, the use of ondansetron as a medication to prevent the need for NOWS opioid pharmacologic treatment, and the introduction of symptom-triggered dosing compared with scheduled dosing. Fourth, maternal, infant, environmental, and genetic factors that have been found to be associated with NOWS severity are highlighted. Finally, emerging recommendations on postdelivery hospitalization follow-up and developmental surveillance are presented, along with highlighting ongoing and needed areas of research to promote infant and family well-being for families impacted by opioid use.

Indexed as

Analgesics, OpioidNeonatal Abstinence SyndromePrenatal Exposure Delayed EffectsChild, PreschoolClinical Trials as TopicFemaleHumansInfantInfant, NewbornMethadoneMorphinePregnancyAnalgesics, OpioidMethadoneMorphine

Identifiers

PMID38178779
PMCPMC10827648
OpenAlexW4390612735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.